Related Experiment Video
Updated: Aug 18, 2026

Using Mouse Mammary Tumor Cells to Teach Core Biology Concepts: A Simple Lab Module
Published on: June 18, 2015
Prolactin and 3-methylcholanthrene induced cervical carcinoma. Effect of bromocriptine
Abstract:
Female mice of the NMRI strain were injected with estradil for the first five days after birth (estrogenized animals) and ovariectomized at the ages of 6-9 weeks. One week later, a cotton thread impregnated with 3-methylcholanthrene was inserted into the uterine cervix. Starting on the day of insertion of the thread, and for a further 6 days, the females were injected with estradiol (E2), ovine prolactin (P), or 2-bromo-alpha-ergokryptine mesylate (bromocriptine). Controls were injected with vehicles only. The animals were killed 4 or 8 weeks after insertion of the thread, and the uterine cervix was serially sectioned. A combined treatment with E2 and P resulted in an increased incidence of invasive epithelial lesions in the uterine cervix. This incidence was higher than in controls or females injected with either hormone separately. Bromocriptine reduced the incidence of invasions, and this reduction with either hormone separately. Bromocriptine reduced the incidence of invasion, and this reduction could not be restored to the contrl level by a simultaneous treatment with E2 anrogenized females was higher than that reported in an earlied study using non-estrogpenized females.
More Related Videos
13:43Intraductal Delivery and X-ray Visualization of Ethanol-Based Ablative Solution for Prevention and Local Treatment of Breast Cancer in Mouse Models
Published on: April 1, 2022
12:57X-Ray Visualization of Intraductal Ethanol-Based Ablative Treatment for Prevention of Breast Cancer in Rat Models
Published on: December 9, 2022
Related Concept Videos
Mutagenicity and Carcinogenicity
Direct-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship
The direct-acting...
Direct-Acting Cholinergic Agonists: Pharmacokinetics
Direct-Acting Cholinergic Agonists: Therapeutic Uses
Cholinergic Antagonists: Pharmacokinetics